Outcomes reported by patients during de-intensification of complex insulin therapy regimens for type 2 diabetes mellitus

In modern diabetology, there is a growing interest in patient-reported outcomes (COI) as an important indicator influencing the effectiveness of therapy. This review analyzes the effect of de-intensification of complex insulin therapy regimens using the drug Iglarlixi (a combination of insulin glargine 100 U/ml and lixisenatide) on the quality of life and satisfaction with treatment in patients with type 2 diabetes mellitus (T2DM). The results of key studies (SoliSwitch, IDEAL, SIMPLIFY Japan) are reviewed, demonstrating a significant improvement in COI indicators when switching from multiple injections of insulin or ready-made mixtures to a single injection of Iglarlixi. The most pronounced improvements were noted in the domains “Burden of treatment” and “Diabetes management”. Given the influence of psychosocial factors on the perception of therapy and treatment adherence, de-intensification of insulin therapy may be especially important for patients experiencing stigmatization and diabetic distress. The review results confirm that switching to Iglarlixi is an effective de-intensification strategy that improves both glycemic control and quality of life in patients with T2DM.

1. Holmes-Truscott E, Browne JL, Ventura AD et al. Diabetes stigma is associated with negative treatment appraisals among adults with insulin-treated type 2 diabetes: Results from the second Diabetes MILES – Australia (MILES-2) survey. Diabetic Med. 2018; 35(5): 658–62. doi: 10.1111/dme.13598.

2. Wagner JA, Tennen H, Feinn R, Osborn CY. Self-reported discrimination, diabetes distress, and continuous blood glucose in women with type 2 diabetes. J Immigr Minor Health. 2015; 17(2): 566–73. doi: 10.1007/s10903-013-9948-8.

3. Baucom KJ, Queen TL, Wiebe DJ et al. Depressive symptoms, daily stress, and adherence in late adolescents with type 1 diabetes. Health Psychology. 2015; 34(5): 522–30. doi: 10.1037/hea0000219.

4. Amin MF, Bhowmik B., Rouf R. et al. Assessment of quality of life and its determinants in type-2 diabetes patients using the WHOQOL-BREF instrument in Bangladesh. BMC Endocr Disord. 2022; 22(1): 162. doi: 10.1186/s12902-022-01072-w.

5. Cho MK, Kim MY. What affects quality of life for people with type 1 diabetes?: A cross-sectional observational study. Int J Environ Res Public Health. 2021; 18(14): 7623. doi: 10.3390/ijerph18147623.

6. Alvarado-Martel D, Velasco R, Sanchez-Hernandez RM et al. Quality of life and type 1 diabetes: A study assessing patients' perceptions and self-management needs. Patient Prefer Adherence. 2015; 9: 1315–23. doi: 10.2147/PPA.S87310.

7. Tamornpark R, Utsaha S, Apidechkul T et al. Quality of life and factors associated with a good quality of life among diabetes mellitus patients in northern Thailand. Health Qual Life Outcomes. 2022; 20(1): 81. doi: 10.1186/s12955-022-01986-y.

8. Fadini GP, Ciardullo S, Perseghin G et al. Preferences, expectations and attitudes on basal insulin from patient-physician-payer perspective: A multi-stakeholder survey by the Italian Diabetes Society (ITA4P Study). Diabetes Ther. 2025; 16(1): 123–30. doi:10.1007/s13300-025-01729-4.

9. Ishii H, Kamiya H, Takahashi Y, Morimoto Y, Yabe D. Quality of life in Japanese people with type 2 diabetes switching from multiple daily insulin injections to once-daily iGlarLixi: SIMPLIFY Japan. Diabetes Ther. 2024; 15(11): 2381–400. doi:10.1007/s13300-024-01645-z.

10. Haluzík M, Cypryk K, Alvarez A et al. Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli-SWITCH study. Diabetes Obes Metab. 2025; 27(5): 2730–39. doi:10.1111/dom.16276.

11. Brod M, Christensen T, Hammer M et al. Examining the ability to detect change using the TRIM-Diabetes and TRIM-Diabetes Device measures. Qual Life Res. 2011; 20(9): 1513–18. doi: 10.1007/s11136-011-9886-7.

12. Polonsky WH. Improved patient- and physician-reported outcomes with iGlarLixi when switching from premixed insulin in people with type 2 diabetes (T2D): The Soli-Switch study. Short oral on poster presentation at: 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025); March 20, 2025. Amsterdam, Netherlands.

13. Polonsky WH, Giorgino F, Rosenstock J et al. Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial. Diabetes Obes Metab. 2022; 24(12): 2364–72. doi: 10.1111/dom.14822.

14. Zizka O. Insulin therapy de-intensification with iGlarLixi (IDEAL) randomised controlled trial: Patient-reported outcomes. Oral presentation at: 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025). March 21, 2025. Amsterdam, Netherlands.

15. Bradley C. The Diabetes Treatment Satisfaction Questionnaire: DTSQ. In Bradley C (Ed) Handbook of psychology and diabetes: A guide to psychological measurement in diabetes research and practice. Abingdon: Routledge. 1994; 111–32. ISBN: 9783718655625.

16. Ishii H. Development and psychometric validation of the Diabetes Therapy-Related QOL (DTR-QOL) questionnaire. J Med Econ. 2012; 15(3): 556–63. doi: 10.3111/13696998.2012.665111.

17. Pilla SJ, Meza KA, Schoenborn NL et al. A qualitative study of perspectives of older adults on deintensifying diabetes medications. J Gen Intern Med. 2023; 38(4): 1008–15. doi: 10.1007/s11606-022-07828-3.

18. Pilla SJ, Jalalzai R, Tang O et al. A national survey of physicians' views on the importance and implementation of deintensifying diabetes medications. J Gen Intern Med. 2024; 39(6): 992–1001. doi: 10.1007/s11606-023-08506-8.

19. Wrzal PK, Mohseni AA, Fournier C et al. Persons with diabetes and general/family practitioner perspectives related to therapeutic inertia in type 2 diabetes mellitus using qualitative focus groups and the theoretical domains framework: Results from the MOTION study. Can J Diabetes. 2022; 46(2): 171–80. doi: 10.1016/j.jcjd.2021.08.004.

20. Roldan Munoz S, Mol PGM, de Vries F et al. Perspectives of people with type 2 diabetes mellitus towards a decision aid assessing preferences of glucose-lowering drugs: The dilemma of choosing. Patient Prefer Adherence. 2025; 19: 215–34. doi: 10.2147/PPA.S486553.

21. Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: Recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016; 10:1299–307. doi: 10.2147/PPA.S106821.

22. Beato-Víbora PI, Chico A, Moreno-Fernandez J et al. Transitioning between automated insulin delivery systems: A focus on personalisation. Diabetes Res Clin Pract. 2025; 222: 112070. doi: 10.1016/j.diabres.2025.112070.

23. Shubrook JH, Radin M, Ali SN et al. Preference for type 2 diabetes therapies in the United States: A discrete choice experiment. Adv Ther. 2022; 39(9): 4114–30. doi: 10.1007/s12325-022-02181-7.

24. Aroda VR, Rosenstock J, Wysham C et al.; LixiLan-L Trial Investigators. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: The LixiLan-L randomized trial. Diabetes Care. 2016; 39(11): 1972–80.doi: 10.2337/dc16-1495.

25. Weatherall J, Polonsky WH, Lanar S et al. When insulin degludec enhances quality of life in patients with type 2 diabetes: A qualitative investigation. Health Qual Life Outcomes. 2018; 16(1): 87. doi: 10.1186/s12955-018-0883-1.

26. Mekashaw Bayked E, Haile Kahissay M, Demeke Workneh B. The “Life-World” trip of type 2 diabetes patients with allopathic treatment options: A triangulated qualitative investigation. Ann Med. 2022; 54(1): 2714–24.doi: 10.1080/07853890.2022.2122552.